<DOC>
	<DOCNO>NCT01124643</DOCNO>
	<brief_summary>This study evaluate safety clinical outcome treatment Replagal adult participant Fabry disease complete Study TKT028 ( NCT00864851 ) .</brief_summary>
	<brief_title>Extension Study TKT028 Evaluating Safety Clinical Outcomes ReplagalÂ® Adult Patients With Fabry Disease</brief_title>
	<detailed_description>HGT-REP-060 design provide participant participate TKT028 additional 52 week treatment Replagal standard dose 0.2 milligram per kilogram ( mg/kg ) every week ( EOW ) ass effect continue Replagal therapy long-term safety clinical outcome participant population .</detailed_description>
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Complete study requirement assessment Study TKT028 le 30 day ( +/ 7 day ) prior first dose extension protocol Voluntarily sign Institutional Review Board/Independent Ethics Committee approve informed consent form relevant aspect study explain discuss . Has receive tolerate least 80 % total planned Replagal infusion Study TKT028 Female participant childbearing potential must agree use medically acceptable method contraception time study must negative pregnancy test time study entry require throughout participation study Has receive treatment investigational drug ( Replagal ) device within 30 day prior study entry . Is unable comply protocol , ( eg , unable return safety evaluation , otherwise unlikely complete study ) , determine Investigator Has positive test hepatitis B surface antigen ( HBsAg ) , hepatitis C ( HCV ) antibody , human immunodeficiency virus ( HIV ) antibody Is pregnant lactating Is morbidly obese , define body mass index ( BMI ) &gt; 39 kg/m2 Has safety medical issue , assess Investigator , contraindicate participation study ( eg , experienced adverse reaction treatment Replagal know hypersensitivity component Replagal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Replagal</keyword>
	<keyword>Agalsidase alfa</keyword>
	<keyword>Alpha-Galactosidase</keyword>
	<keyword>Enzyme Replacement Therapy</keyword>
</DOC>